Clinical Trial Update: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial of a conditioning regimen including an iodine-131 labeled monoclonal antibody with fludarabine, cyclophosphamide, total-body irradiation, and dono…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia in Remission
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Acute Myeloid Leukemia in Remission
• Anemia with Excess Blasts
• Anemia with Ring Sideroblasts
• Cytopenia with Multilineage Dysplasia
• Cytopenia with Multilineage Dysplasia and Ring Sideroblasts
• Myelomonocytic Leukemia
• Previously Treated Myelodysplastic Syndrome

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Donor bone marrow transplant
• Fludarabine phosphate (Fludarabine phosphate)
• Total Body Irradiation
• iodine-131 monoclonal antibody BC8 (iodine-131 labeled monoclonal antibody BC8)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Status: TERMINATED | Results posted: 2023-02-09